| Document |
Document Title |
|
WO/1989/000558A1 |
Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl)amides of the formula (I): HOC(O)-(CH2)n-C(O)-N(R1)-CH2CH2SO3 - + HN(R2)3, wherein R1 is selected from the group consisting of hydrogen, C1-C8 alkyl and phenyl, R2 is C1-C...
|
|
WO/1989/000578A1 |
New 11beta-phenyl-4,9,15-estratrienes have general formula (I) where X is an oxygen atom or an N-OH hydroxyimino grouping, R1 is a hydrogen atom or a methyl group, R2 is a hydrogen atom, or an alkyl or acyl residue with 1 to 10 carbon at...
|
|
WO/1988/008002A1 |
This invention provides novel cyclic hydrocarbons of formula (I), wherein R is selected from the group consisting of CH2=CH-CH2-, HO-CH2CH2CH2-, and CH3; wherein R1 is selected from the group consisting of m-trifluoromethylphenylmethyl, ...
|
|
WO/1988/007545A1 |
Pregnane derivatives represented by general formula (I) (wherein A1 represents a hydrogen atom or a hydroxy group, A2 represents a substituent such as a hydroxy group when A1 represents a hydrogen atom, or A2 represents a hydrogen atom w...
|
|
WO/1988/007051A1 |
New 19, 11beta-bridged steroids having the general formula (I), in which R' signifies a methyl or ethyl residue; R2 signifies a hydrogen or chlorine atom or a C1-C4 alkyl residue; B and G, which are identical or different, signify respec...
|
|
WO/1988/003534A1 |
17beta-Cyano-17alpha-hydroxy steroids (I) are transformed to 17alpha-halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoids (III...
|
|
WO/1988/002753A2 |
New 9-alpha-hydroxy steroids are prepared by the introduction of substituents on the D-ring of 9-alpha-hydroxy-androst-4-ene-3,17-dione. The resulting compounds are useful intermediates in the synthesis of corticosteroids.
|
|
WO/1988/001868A1 |
Steroids of formula (I) which are characterized by a 17alpha-cyanomethyl, azidomethyl, methoxymethyl, phenylmethyl, or ethynylmethyl substituent and a 17beta-hydroxy/esterified hydroxy substituent. The steroids of this invention have glu...
|
|
WO/1988/000470A1 |
Ova and embryo losses are reduced, and hence fecundity is increased, in a flock of sheep or a group of other domesticated animals by actively immunizing the female animals in the flock or group against a group of steroids which group com...
|
|
WO/1988/000202A1 |
Compounds obtained from the associative synthesis of sulfur-containig or sulfur-free amino-acids with derivatives of DELTA-4 pregnene 3,20-dione or with derivatives of DELTA-1,4 pregnadiene 3,20-dione having the general formulae (I), (II...
|
|
WO/1987/006936A1 |
Sodium salt of sialosylcholesterol which has an excellent solubility in water and is useful as a drug for treating various diseases induced by disturbances of a peripheral or central nervous system.
|
|
WO/1987/006706A1 |
Qualitative and quantitive electrochemiluminescent assays for analytes of interest present in multicomponent liquids. These methods comprise contacting a sample with a reagent labeled with an electrochemiluminescent chemical moiety and c...
|
|
WO/1987/005908A1 |
Products having the formula (I) wherein R1 is an aryl or aralkyl, R2 is a hydrocarbonated radical (1-18 carbon atoms), the dotted lines indicate an optional bond, the cycles A, B and C represent (II), (III), (IV), (V), (VI); R' and R'' a...
|
|
WO/1987/005028A1 |
Compounds of formula (I), wherein one X is COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; remaining X's are H, F, CH3, OH, COOR, CH2COOR, CH(COOR)2, CONHR, CH2CONHR, or CN; Y is (i1), (i2), (i3), (i4), or (i5); R is H, alkyl of 1-5 ca...
|
|
WO/1987/004166A1 |
Compounds (I) (either R1 = OH, C1-C4 alkoxy and R2 = H, C1-C4 alkyl, or R1 + R2 = a chemical bond; R3 = an aminodeoxy or aminodideoxy or aminotrideoxy sugar residue of the D and L series, the glycosidic linkage being alpha or beta: and e...
|
|
WO/1987/002672A1 |
Novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of formula (I), wherein R15 is = O or -OH; wherein R23 with R10 forms a cyclic phosphate of formula (II) or wherein R23 is...
|
|
WO/1987/002367A2 |
Provided are cyclic hydrocarbons of Formula (I) with an aminoalkyl sidechain that are useful for treating phospholipase A2-mediated conditions, diabetes and obesity.
|
|
WO/1987/001706A2 |
Disclosed are DELTA9(11)-steroids (VI) and amino substituted steroids of formula (XI), which contain an amino group attached to the terminal carbon atom of the C17-side chain, more particularly amino steroids (Ia and Ib), aromatic steroi...
|
|
WO/1987/000175A1 |
9alpha, 11beta and 11beta-susbstituted estranes which exhibit elevated estrogenic and postcoital contraceptive activities. A process for their manufacture and their use in pharmaceuticals is also disclosed.
|
|
WO/1986/003299A1 |
An immunoassay for cholesterol epoxide. To prepare the antibodies used in the immunoassay, novel immunogens, are prepared which comprise a 3,5(6)-transdiaxial-dihydroxycholestane-6(5)-yl-hapten adduct linked to a covalently bonded bridge...
|
|
WO/1986/001502A1 |
A process for the production of amino compounds from hydroxyl compounds (Voelter reaction), according to which a hydroxyl compound is converted with trifluormethanesulphonic acid anhydride in water-free conditions, the corresponding trif...
|
|
WO/1986/000907A1 |
A process for the manufacture of 6alpha-methyl steroids having general formula (I) in which X is a hydroxy group and Y a hydrogen atom, or X and Y are together a carbon-carbon bond and R1 is a cyano group, an acetyl group or an alkanoylo...
|
|
WO/1986/000908A1 |
Derivatives of 11-desoxy-17alpha-oxicorticosterone of general formula (I) where R = -OC(CH2)nC6H4N(CH2CH2Cl)2, n = 1, 3, having antitumoral, hormonal and immunodepressive activity.
|
|
WO/1986/000311A1 |
Derivatives of steroids of androstane series constituting compounds of a general formula (I); where R1 = -OCOCH2C6H4N(CH2CH2Cl)2; -OH; -O-; R2 = -OCO(CH2)n C6H4N (CH2CH2X)2, where n = 1,3; X = Cl, Br, J; -OH; -O-; formula (II); R3 = -CH3...
|
|
WO/1986/000066A1 |
New butyramide derivatives corresponding to formula (I), wherein X and Y independently represent hydroxymethyl; cyano; carboxy; functionally modified carboxy selected from esterified carboxy, carbamoyl, and N-substituted carbamoyl; 5-tet...
|
|
WO/1985/005361A1 |
Novel compounds having the general formula (I), wherein: R1 is hydrogen or an acyl substitutent of formula -(C=O)-R2, wherein: R2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkylene, haloalkyl, aryl, haloaryl or arylalkylene. T...
|
|
WO/1985/000520A1 |
Ester derivatives of gamma-aminobutyric acid (GABA) and GABA analogues which cross the blood-brain barrier, as well as methods of synthesizing and using the compounds. The ester derivatives have the formula (I), where A is a radical comp...
|
|
WO/1983/003414A1 |
The esters are represented by the formula (I), wherein R1 and R2, which may be the same or different, are the rest of an amino acid, from the carbon atom in the beta position (if it is present), R3 is the rest of a steroid or of a pharma...
|
|
WO/1983/003099A1 |
The invention relates to products having the general formula I, wherein R1 is thienyl or phenyl optionally substituted, furyl, cycloalkyl, naphtyl, phenyl-phenyl, alkyl or alkenyl; R2 is methyl or ethyl; R3 is H, OH, alkyl, alkenyl, opti...
|
|
WO/1983/000694A1 |
A nondenaturing zwitterionic detergent for proteins which, for example, consists of an effective amount of 3- AD(3-cholamidopropyl)dimethylammonio BD-1-propanesulfonate (CHAPS). This detergent is of extreme interest in the biological stu...
|
|
WO/1982/003175A1 |
Waster-soluble complex compounds obtained by binding albumin to a half ester of organic dibasic acid such as succinic acid or phthalic acid with 7-hydroxycholesterol, represented by the general formula: (FORMULA) wherein R represents a p...
|
|
WO/1980/002024A1 |
Lepidoptericidal and herbicidal active compounds having the generic formula (FORMULA) wherein R, R1, R2 and R3 are as disclosed herein. In general, these compounds show enhanced lepidoptericidal activity and show reduced phytotoxic effec...
|
|
JP7468865B2 |
To provide a novel catalyst to solve the problem that a sponge catalyst conventionally used in, for example, hydrogeneration of organic compounds, such as nitryl compounds and the like is extremely unstable even in atmosphere and has a r...
|
|
JP7463006B2 |
Disclosed are cationic lipids which are compounds of Formula I. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly ca...
|
|
JP2024514228A |
The present disclosure describes dihydrogen phosphate ((((E)-1-((8S,9S,10R,13S,14S,17S)-10,13 -dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradec
ahydro-1H-cyclopenta[a]phenanthren-17-yl )ethylidene)amino)oxy)methyl) and its pha...
|
|
JP2024032912A |
The present invention provides cationic lipids that are compounds of formula I. The cationic lipids provided herein can be useful for the delivery and expression of mRNA and encoded proteins, e.g., as components of liposome delivery vehi...
|
|
JP2024028916A |
The present invention provides compounds useful for treating disorders and diseases associated with increased levels of estradiol and/or treatable by inhibition of the 17β-HSD1 enzyme. Furthermore, compounds are provided that exhibit li...
|
|
JP2024502948A |
This disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials, and methods of using them. [Selection diagram] None
|
|
JP7384903B2 |
The present invention relates to fulvestrant prodrugs of formula II and process for the preparation thereof. The present disclosure also relates to pharmaceutical composition of fulvestrant prodrugs and method of treatment using the same.
|
|
JP7382326B2 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
JP2023153988A |
To provide novel glucocorticoids and novel therapies that minimize side effects arising from glucocorticoid administration, particularly those arising from activating glucocorticoid receptors in non-target cells.Provided herein are prote...
|
|
JP2023542365A |
The present invention uses isopropyl alcohol to separate and purify sodium taurodeoxycholate commercially using a batch washing method, which simplifies the process, produces fewer by-products, and reduces impurity. The present invention...
|
|
JP2023539125A |
The present invention provides certain substituted (3α,5β)-3-hydroxy-pregnan-20-ones in free form, pharmaceutically acceptable salt form and/or substantially pure form as described herein; Pharmaceutical compositions thereof and method...
|
|
JP7317898B2 |
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3a, R3b, R4, R5a, R5b, R6a, and R6b are as defined herein. Compounds of the present ...
|
|
JP2023532343A |
The present disclosure relates to compositions derived from bio-accessible molecules such as amino acids and/or steroids. In particular, the composition can be a monomer, polymer or copolymer derived from amino acid dimers. Such composit...
|
|
JP2023526674A |
A cationic steroid antimicrobial (CSA) compound having the structure of Formula I, II or III, or a salt thereof, wherein R1~R18at least one of (e.g., R18) contains a terpenyl group attached through an ester or amide linkage, and R1~R18at...
|
|
JP2023523931A |
Molecules comprising a G protein-coupled estrogen receptor (GPER) ligand linked to a linker linked to an E3 ubiquitin ligase ligand and methods of using the molecules are provided. In one embodiment, the GPER ligand is estradiol and the ...
|
|
JP2023071910A |
To provide pharmaceuticals that are neuroactive and suitable for use as an anesthetic.The present invention is generally directed to neuroactive 19-alkoxy-17-substituted steroids with the structure in the figure and pharmaceutically acce...
|
|
JP2023518381A |
The present disclosure provides crystalline polymorphs of squalamine phosphate, methods of making the same, and methods of treatment using the same.
|
|
JP2023516759A |
Provided herein are compositions, methods of manufacture thereof, and methods for targeted delivery of therapeutic agents to alter the expression and function of target genes, e.g., proteins involved in lipid and cholesterol metabolism, ...
|
